Shares of Repare Therapeutics (NASDAQ:RPTX) plunged 38% in post-market trading Thursday after the company reported Phase 1 data on its drugs lunresertib and camonsertib as a combination therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback